On October 26, Zhuzhou SDIC Venture Capital Co., Ltd. (hereinafter referred to as "SDIC Venture Capital"), a wholly-owned subsidiary of SDIC Group, self-managed fund Zhuzhou SDIC Venture Private Equity Fund Partnership (Limited Partnership) (hereinafter referred to as "Chuangying Fund"), an investment enterprise invested by Sichuan Huiyu Pharmaceutical Co., Ltd. (stock abbreviation: Huiyu Pharmaceutical, stock code: 688553) was listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange.
Listing bell ringing ceremony site
The thank-you meeting is on-site
Founded in 2010, Huiyu Pharmaceutical is an international pharmaceutical enterprise integrating the research and development, production and sales of anti-tumor drugs, and has won the honor of "the most growing enterprise in China's pharmaceutical industry in 2021". The company's injection of pemetrexed, azacitidine and other varieties of domestic market share ranked first; Oxaliplatin, paclitaxel, bendamustine hydrochloride and other varieties have successively won the bid for collection; A number of varieties such as pleshafu and butylphthalide have been declared for registration and approval. The company closely follows the national medical reform strategy, participates in a number of "major national new drug creation major science and technology projects", and becomes a "dark horse enterprise" in the new medical reform. The product pipeline layout continued to expand, and 7 first-line anti-tumor injections such as pemetractroxed disodium, docetaxel and paclitaxel for injection passed the consistency evaluation, of which 6 had won the bid for the national "4 + 7" centralized procurement. 11 products were approved in the UK and commercially marketed in many EU countries.
Renderings of the Innovative Drug Research Institute under construction by Huiyu Pharmaceutical
In December 2019, Chuangying Fund invested in Huiyu Pharmaceutical. In less than two years, Huiyu Pharmaceutical has been successfully listed, and it has also become the first listed enterprise invested by SDIC Venture Capital, and at the same time, it is also one of the important achievements of SDIC Venture Capital in implementing market-oriented transformation reforms.
In addition to Huiyu Pharmaceutical, SDIC Venture Capital has also invested in a number of high-quality projects in the field of biomedicine, such as Zhonghui Yuantong, Tongyuankang, Tianjing Biological (Hangzhou), Thermoroth, Maiji Biological, Puguang Technology and so on. In accordance with the strategic deployment of the Municipal Party Committee and the Municipal Government, the company accelerates the construction of the medical device industrial park, boosts the local medical enterprises to become bigger and stronger through capital operation, and introduces more medical enterprises to Zhuzhou through capital investment, so as to build a solid support for Zhuzhou's big health industry to become bigger and stronger.
In the future, SDIC Venture Capital will deeply implement the spirit of the 13th Party Congress of Zhuzhou City, actively focus on zhuzhou's "3+3+2" modern industrial system in accordance with the work idea of "focus, fission, innovation, upgrading and brand", and contribute to the implementation of the "three highs and four new" strategy, the cultivation of a famous manufacturing city, the construction of a happy Zhuzhou, and the effort to write a magnificent chapter of modern Zhuzhou.
Author: Long Wensheng Liu Zihao
Photo: Liu Zihao
Editor: Zhang Hantao Ding Ming
Review: Huang Shou